Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enliven Therapeutics, Inc.ELVN · Entity 4024 | Director · PRESIDENT AND CEO | November 17, 2025 | November 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enliven Therapeutics, Inc.
Report date November 17, 2025 · Filed November 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 890,392 |
Reported balance
After 2025-11-17 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-11-17 · Sale · Disposed 12,500 · Balance 890,392 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2: This transaction was executed in multiple trades at prices ranging from $21.37 to $22.3537. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
F2: This transaction was executed in multiple trades at prices ranging from $21.37 to $22.3537. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 17, 2025 Filed Nov 19, 2025 18:45 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 12,500 | $21.82 | $272,738.75 |
DisclosureSEC source: 0001967168-25-000008 · form4-11192025_111110.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 890,392 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.37 to $22.3537. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| October 17, 2025 Filed Oct 21, 2025 18:13 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 12,500 | $21.33 | $266,653.75 |
DisclosureSEC source: 0001967168-25-000007 · form4-10212025_101038.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 902,892 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.1303 to $21.88. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 17:51 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,700 | $20.06 | $74,227.55 |
DisclosureSEC source: 0001967168-25-000006 · form4-09302025_090944.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 915,392 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.27. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| September 23, 2025 Filed Sep 25, 2025 19:42 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 2,800 | $20.03 | $56,084.00 |
DisclosureSEC source: 0001967168-25-000005 · form4-09252025_110953.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 919,092 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| September 19, 2025 Filed Sep 19, 2025 19:12 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,000 | $20.25 | $20,250.00 |
DisclosureSEC source: 0001967168-25-000004 · form4-09192025_110913.xml · nonDerivative · entry 2 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 921,892 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $20.015 to $20.035. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| September 17, 2025 Filed Sep 19, 2025 19:12 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 5,000 | $19.09 | $95,473.00 |
DisclosureSEC source: 0001967168-25-000004 · form4-09192025_110913.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 922,892 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.56 to $19.51. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| August 20, 2025 Filed Aug 21, 2025 18:48 UTC Amendment | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,517 | $20.00 | $30,343.49 |
DisclosureSEC source: 0001415889-25-022649 · form4a-08212025_100826.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 927,892 F1 · security: The original Form 4, filed August 20, 2025, did not reflect the stock sale on August 20, 2025. F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F4 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| August 19, 2025 Filed Aug 20, 2025 16:36 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 590 | $20.00 | $11,800.00 |
DisclosureSEC source: 0001415889-25-022459 · form4-08202025_080850.xml · nonDerivative · entry 2 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 929,409 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 16:36 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 10,393 | $20.02 | $208,106.31 |
DisclosureSEC source: 0001415889-25-022459 · form4-08202025_080850.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 929,999 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.75 to $20.715. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 19:21 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,663 | $23.37 | $85,606.51 |
DisclosureSEC source: 0001415889-25-020087 · form4-07212025_110705.xml · nonDerivative · entry 3 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 940,392 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F5 · price: This transaction was executed in multiple trades at prices ranging from $23.285 to $23.595. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 19:21 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 4,687 | $22.69 | $106,359.75 |
DisclosureSEC source: 0001415889-25-020087 · form4-07212025_110705.xml · nonDerivative · entry 2 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 944,055 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $22.28 to $23.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 19:21 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 4,150 | $21.58 | $89,551.61 |
DisclosureSEC source: 0001415889-25-020087 · form4-07212025_110705.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 948,742 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.26 to $22.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 18:22 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,998 | $22.75 | $45,453.30 |
DisclosureSEC source: 0001415889-25-017730 · form4-06182025_100643.xml · nonDerivative · entry 2 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 952,892 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $22.5945 to $22.9964. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 18:22 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 10,502 | $22.08 | $231,839.00 |
DisclosureSEC source: 0001415889-25-017730 · form4-06182025_100643.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 954,890 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.5935 to $22.5793. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 16:53 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 7,500 | $20.05 | $150,351.75 |
DisclosureSEC source: 0001415889-25-015785 · form4-06052025_080630.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 965,392 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| May 19, 2025 Filed May 21, 2025 18:29 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 5,000 | $16.49 | $82,453.00 |
DisclosureSEC source: 0001415889-25-013992 · form4-05212025_100549.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 972,892 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.11 to $16.90. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| May 02, 2025 Filed May 5, 2025 18:42 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 2,170 | $20.00 | $43,408.68 |
DisclosureSEC source: 0001415889-25-012030 · form4-05052025_100514.xml · nonDerivative · entry 2 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 977,892 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| May 01, 2025 Filed May 5, 2025 18:42 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 5,330 | $20.08 | $107,006.68 |
DisclosureSEC source: 0001415889-25-012030 · form4-05052025_100514.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 980,062 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| April 17, 2025 Filed Apr 21, 2025 17:55 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 5,000 | $16.42 | $82,096.00 |
DisclosureSEC source: 0001415889-25-011121 · form4-04212025_090428.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 985,392 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.09 to $16.68. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 17:42 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 12,500 | $20.83 | $260,320.00 |
DisclosureSEC source: 0001415889-25-008609 · form4-03192025_090346.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 990,392 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.09 to $21.04. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 17:28 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 490,000 | $0.00 Strike: $22.47 | $0.00 |
DisclosureSEC source: 0001415889-25-003512 · form4-02102025_100227.xml · derivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 490,000 Underlying: Common Stock · 490,000 shares Expires 2035-02-06 F1 · derivative.exercise_date: 1/4th of the shares subject to the option will vest on February 6, 2026 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 16:21 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 924 | $30.00 | $27,722.68 |
DisclosureSEC source: 0001415889-24-025503 · form4-10222024_081007.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,002,892 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| October 09, 2024 Filed Oct 10, 2024 20:38 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 2,830 | $28.53 | $80,729.71 |
DisclosureSEC source: 0001415889-24-024991 · form4-10112024_121018.xml · nonDerivative · entry 4 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,003,816 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F5 · price: This transaction was executed in multiple trades at prices ranging from $28.51to $28.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| October 09, 2024 Filed Oct 10, 2024 20:38 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 13,880 | $28.07 | $389,675.45 |
DisclosureSEC source: 0001415889-24-024991 · form4-10112024_121018.xml · nonDerivative · entry 3 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,006,646 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $27.50 to $28.43. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 20:38 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 100 | $28.51 | $2,851.00 |
DisclosureSEC source: 0001415889-24-024991 · form4-10112024_121018.xml · nonDerivative · entry 2 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,020,526 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 20:38 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 13,167 | $27.95 | $368,078.22 |
DisclosureSEC source: 0001415889-24-024991 · form4-10112024_121018.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,020,626 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.50 to $28.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 18:57 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 2,730 | $27.50 | $75,075.00 |
DisclosureSEC source: 0001415889-24-024901 · form4-10082024_101015.xml · nonDerivative · entry 2 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,033,793 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 18:57 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 12,206 | $27.51 | $335,791.94 |
DisclosureSEC source: 0001415889-24-024901 · form4-10082024_101015.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,036,523 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.50 to $27.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 18:45 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 526 | $27.54 | $14,484.51 |
DisclosureSEC source: 0001415889-24-024671 · form4-10032024_101054.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,048,729 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.52 to $27.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 19:48 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 12,000 | $22.89 | $274,718.40 |
DisclosureSEC source: 0001415889-24-022512 · form4-08282024_110802.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,049,255 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.60 to $23.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 19:25 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 2,270 | $27.56 | $62,555.07 |
DisclosureSEC source: 0001415889-24-020687 · form4-08022024_110802.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,061,255 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.50 to $27.655. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 17:39 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 43 | $25.83 | $1,110.67 |
DisclosureSEC source: 0001415889-24-020265 · form4-07292024_090754.xml · nonDerivative · entry 3 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,063,525 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F5 · price: This transaction was executed in multiple trades at prices ranging from $25.8172 to $25.8413. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 17:39 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 8,164 | $25.10 | $204,919.67 |
DisclosureSEC source: 0001415889-24-020265 · form4-07292024_090754.xml · nonDerivative · entry 2 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,063,568 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $24.81 to $25.7811. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 17:39 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,793 | $24.53 | $93,042.29 |
DisclosureSEC source: 0001415889-24-020265 · form4-07292024_090754.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,071,732 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $23.81 to $24.8005. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 16:35 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 578 | $22.30 | $12,887.09 |
DisclosureSEC source: 0001415889-24-018336 · form4-06272024_080620.xml · nonDerivative · entry 2 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,075,525 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $22.2588 to $22.3613. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 16:35 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 11,422 | $21.63 | $247,014.46 |
DisclosureSEC source: 0001415889-24-018336 · form4-06272024_080620.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,076,103 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.25 to $22.2438. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. Read SEC document |
| May 28, 2024 Filed May 30, 2024 17:56 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001415889-24-014915 · form4-05302024_090556.xml · derivative · entry 8 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,841 Underlying: Common Stock · 12,000 shares Expires 2030-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F7 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| May 28, 2024 Filed May 30, 2024 17:56 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 100 | $24.34 | $2,434.00 |
DisclosureSEC source: 0001415889-24-014915 · form4-05302024_090556.xml · nonDerivative · entry 4 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| May 28, 2024 Filed May 30, 2024 17:56 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 5,219 | $23.57 | $123,019.66 |
DisclosureSEC source: 0001415889-24-014915 · form4-05302024_090556.xml · nonDerivative · entry 3 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $23.28 to $23.96. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 28, 2024 Filed May 30, 2024 17:56 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 6,681 | $22.86 | $152,756.39 |
DisclosureSEC source: 0001415889-24-014915 · form4-05302024_090556.xml · nonDerivative · entry 2 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,319 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.275 to $23.2719. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 28, 2024 Filed May 30, 2024 17:56 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 12,000 | $1.12 | $13,440.00 |
DisclosureSEC source: 0001415889-24-014915 · form4-05302024_090556.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 18:50 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001415889-24-011707 · form4-04292024_100422.xml · derivative · entry 6 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200,841 Underlying: Common Stock · 12,000 shares Expires 2030-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F6 · derivative.exercise_date: The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 18:50 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 12,000 | $16.89 | $202,700.40 |
DisclosureSEC source: 0001415889-24-011707 · form4-04292024_100422.xml · nonDerivative · entry 2 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.5946 to $17.336. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 18:50 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 12,000 | $1.12 | $13,440.00 |
DisclosureSEC source: 0001415889-24-011707 · form4-04292024_100422.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 19:05 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 47,709 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001415889-24-010828 · form4-04152024_110408.xml · derivative · entry 6 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 212,841 Underlying: Common Stock · 47,709 shares Expires 2030-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F6 · derivative.exercise_date: The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 19:05 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 47,709 | $25.04 | $1,194,700.15 |
DisclosureSEC source: 0001415889-24-010828 · form4-04152024_110408.xml · nonDerivative · entry 2 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.485. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 19:05 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 47,709 | $1.12 | $53,434.08 |
DisclosureSEC source: 0001415889-24-010828 · form4-04152024_110408.xml · nonDerivative · entry 1 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 17:03 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001415889-24-009220 · form4-03272024_090352.xml · derivative · entry 7 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260,550 Underlying: Common Stock · 12,000 shares Expires 2030-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F7 · derivative.exercise_date: The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 17:03 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 4,671 | $18.16 | $84,841.24 |
DisclosureSEC source: 0001415889-24-009220 · form4-03272024_090352.xml · nonDerivative · entry 3 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $17.96 to $18.80. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 17:03 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 7,329 | $17.17 | $125,819.87 |
DisclosureSEC source: 0001415889-24-009220 · form4-03272024_090352.xml · nonDerivative · entry 2 Kintz Samuel · CIK 0001967168 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,671 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.90 to $17.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.